Design, synthesis and antitumor activity of 3,4,5-Trisubstituted Isoxazoles

European Journal of Medicinal Chemistry Reports Pub Date : 2024-08-19 DOI:10.1016/j.ejmcr.2024.100203

Kanghui Duan , Fuxing Tan , Hongming Xie , Haiwang Liu , Yingjun Zhang , Huanfeng Jiang , Wanqing Wu

{"title":"Design, synthesis and antitumor activity of 3,4,5-Trisubstituted Isoxazoles","authors":"Kanghui Duan , Fuxing Tan , Hongming Xie , Haiwang Liu , Yingjun Zhang , Huanfeng Jiang , Wanqing Wu","doi":"10.1016/j.ejmcr.2024.100203","DOIUrl":null,"url":null,"abstract":"<div>In this study, 56 isoxazole derivatives were synthesized and their antitumor activity against 9 cancer cells, such as BXPC-3, MiaPaCa-2, PANC-1, MCF-7, HCT-116, HepG2, NCI-H460, A549 and B16 was detected. The results of pharmacological experiments indicated that most compounds exhibit good cytotoxicity against nine cancer cells. Among them, compound 14–3 has an IC50 of 2.4 μM for colon cancer cells HCT-116, which shows the best effect and is better than the broad-spectrum drug 5-Fluorouracil (5-Fu) for the treatment of colon cancer. In addition, 14–3 induces apoptosis and leads to cell cycle arrest in the G2/M phase. Cytotoxicity tests on human normal hepatocytes LO2 also demonstrates that 14–3 is less toxic than 5-Fu with no obvious toxicity. These results suggest that 14–3 is a potential candidate for the development of anti-tumor drugs.</div>","PeriodicalId":12015,"journal":{"name":"European Journal of Medicinal Chemistry Reports","volume":"12 ","pages":"Article 100203"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S277241742400075X/pdfft?md5=d9d5bb3d63fdd470bae8fe1359c4c765&pid=1-s2.0-S277241742400075X-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medicinal Chemistry Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S277241742400075X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

In this study, 56 isoxazole derivatives were synthesized and their antitumor activity against 9 cancer cells, such as BXPC-3, MiaPaCa-2, PANC-1, MCF-7, HCT-116, HepG2, NCI-H460, A549 and B16 was detected. The results of pharmacological experiments indicated that most compounds exhibit good cytotoxicity against nine cancer cells. Among them, compound 14–3 has an IC₅₀ of 2.4 μM for colon cancer cells HCT-116, which shows the best effect and is better than the broad-spectrum drug 5-Fluorouracil (5-Fu) for the treatment of colon cancer. In addition, 14–3 induces apoptosis and leads to cell cycle arrest in the G2/M phase. Cytotoxicity tests on human normal hepatocytes LO2 also demonstrates that 14–3 is less toxic than 5-Fu with no obvious toxicity. These results suggest that 14–3 is a potential candidate for the development of anti-tumor drugs.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

3,4,5-三取代异噁唑的设计、合成和抗肿瘤活性

本研究合成了 56 种异噁唑衍生物，并检测了它们对 BXPC-3、MiaPaCa-2、PANC-1、MCF-7、HCT-116、HepG2、NCI-H460、A549 和 B16 等 9 种癌细胞的抗肿瘤活性。药理实验结果表明，大多数化合物对九种癌细胞具有良好的细胞毒性。其中，化合物 14-3 对结肠癌细胞 HCT-116 的 IC50 为 2.4 μM，效果最好，优于治疗结肠癌的广谱药物 5-氟尿嘧啶（5-Fu）。此外，14-3 还能诱导细胞凋亡，并导致细胞周期停滞在 G2/M 期。对人类正常肝细胞 LO2 的细胞毒性测试也表明，14-3 的毒性低于 5-Fu，且无明显毒性。这些结果表明，14-3 是一种潜在的候选抗肿瘤药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

European Journal of Medicinal Chemistry Reports

CiteScore

4.50

自引率

0.00%

发文量